Clinical Trial

Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Suspended Phase 3
View on ClinicalTrials.gov →
Why the trial stopped
Study temporarily suspended due to company acquisition and ongoing strategic evaluation of the program
Summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Protocol Amendment History 3 changes
critical Recruitment suspended 2026-06-19
notable Primary completion pushed: 2027-08 -> 2029-06 2026-06-19
minor Completion pushed: 2028-08 -> 2030-07 2026-06-19
Trial Details
NCT Number NCT07020832
Lead Sponsor Apellis Pharmaceuticals, Inc.
Conditions Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant
Enrollment 320 participants
Start Date 2026-05-18
Primary Completion 2029-06 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-18